DR. JOHN D. STRATIGIS, M.D.

Plain English
This study examined how to treat rectal prolapse in children, a condition where part of the rectum slips outside the body. The researchers found that most children respond well to medical treatments, especially bowel management programs, but some older children or those with behavioral issues may require more advanced options. For those cases that don't respond to medication, treatments like sclerotherapy and a specific surgery called transabdominal rectopexy are effective. Who this helps: This information benefits pediatric patients with rectal prolapse and their surgeons.

Plain English
This study looked at whether surgical residents should do their dedicated research after their second or third year of training. Researchers found that 73% of residents completed dedicated research, and those who did it after their second year published more basic science papers (an average of 1 compared to none for those who researched after the third year). This finding matters because residents aiming for fellowships that emphasize basic science research might improve their chances of standing out if they conduct research earlier in their residency. Who this helps: This helps surgical residents looking to enhance their academic profiles and improve their fellowship applications.

Plain English
This study looked at how different surgical methods for removing large lung tumors in unborn babies affect health outcomes. Researchers analyzed data from 85 patients and found that the surgery type (either before birth, during delivery, or immediately after cesarean) did not significantly change survival rates or length of hospital stays, indicating similar effectiveness across methods. The study highlights that using maternal medication and adjusting care strategies can improve outcomes for these high-risk pregnancies, making it crucial to adapt treatment plans accordingly. Who this helps: This helps doctors and healthcare providers make better decisions for pregnant patients facing these complications.

Plain English
This study looked at a treatment called in utero hematopoietic cell transplantation (IUHCT) for babies who have genetic blood disorders, like sickle cell disease. Researchers found that babies receiving this treatment were much less likely to develop graft-versus-host disease (GVHD) compared to newborns who had the same cells transplanted after birth. Specifically, they showed that this resistance was linked to higher levels of a substance called interleukin-10 in fetal blood, which helps regulate the immune response and prevent GVHD. Who this helps: This research benefits patients with congenital blood disorders and their families.

Plain English
This study looked at how a type of immune cell, called regulatory T cells, can help transplant stem cells from a donor into a fetus late in pregnancy. Researchers found that when they added these regulatory T cells to the transplants, the cells successfully integrated and functioned well without causing harmful immune reactions. This is significant because it means that the window for performing these types of transplants could be extended beyond the typical first trimester, potentially benefiting more fetuses at risk of genetic blood disorders. Who this helps: This helps unborn babies with congenital blood disorders.

Plain English
This study looked at a method called in utero transplantation, where stem cells from amniotic fluid are given to a fetus to treat blood disorders that are present at birth. The researchers found that using these amniotic fluid stem cells led to much better long-term integration into the fetal blood system compared to traditional bone marrow stem cells, achieving up to four times higher success rates. This is important because it opens new possibilities for treating serious blood diseases before birth, potentially improving outcomes for affected children. Who this helps: This helps patients with congenital blood disorders and their families.

Plain English
Researchers studied a method to improve the success of transplanting blood-producing cells into unborn babies. They used special nanoparticles containing a drug that helps these cells grow and compete better against the baby’s own cells. With this technique, the transplanted cells were stable and functional for up to 24 weeks, which shows promise for treating genetic blood disorders before birth. Who this helps: This helps unborn babies with severe blood disorders.

Plain English
Researchers developed a way to edit genes in fetal lungs before birth using CRISPR technology, delivering it directly into the amniotic fluid at precisely the right time during pregnancy. In mice with a genetic lung disease that normally kills them at birth, this prenatal gene editing fixed the mutated gene, improved their lung structure, and allowed them to survive. This breakthrough shows that editing genes in the womb could save the lives of babies born with inherited lung diseases that currently have no cure.

Plain English
This study investigated how antibodies from pregnant mice affect the success of fetal stem cell transplants. Researchers found that when the mother's immune system had antibodies against the donor's cells, all of the transplanted cells were rejected by the fetus, leading to a 100% rejection rate in those cases, compared to success in all pregnancies where the mother's antibodies were not harmful. This is important because it highlights the need to test pregnant women for these antibodies before performing stem cell transplants on their babies to improve the chances of successful treatment. Who this helps: This helps patients undergoing fetal stem cell transplants and their doctors.

Plain English
This study explored a technique called in utero transplantation (IUT), where stem cells or other therapeutic substances are introduced into fetuses early in pregnancy, which could allow for treating diseases before birth without the harsh treatments often needed after birth. The researchers developed a method to deliver these cells using two approaches: intravenously and through the amniotic sac, showing that both methods can successfully improve the understanding of treating blood disorders like sickle cell disease and gene therapy. These findings are important because they highlight a potential way to effectively treat congenital conditions early and more safely before a baby is born. Who this helps: Patients with congenital blood disorders and their families.

Plain English
Researchers used CRISPR gene-editing technology to fix faulty genes in mouse fetuses before birth, targeting genes that cause high cholesterol and a fatal liver disease called hereditary tyrosinemia type 1. The edited genes persisted and functioned properly after the mice were born—cholesterol levels dropped in one group, and the other group survived a disease that normally kills them. This proof-of-concept shows that prenatal gene editing could potentially prevent or cure certain genetic diseases before a baby is even born.

Plain English
This study looked at the RNA found in the amniotic fluid of fetuses with a condition called myelomeningocele, a type of spinal defect, to understand the underlying disease processes. They found that fetuses with myelomeningocele had 284 genes with different expression levels compared to healthy fetuses, including genes related to nerve development and inflammation. This matters because it provides new insights into how myelomeningocele affects fetal development, which could help identify new treatment options for this condition. Who this helps: Patients with myelomeningocele and their families.

Plain English
This study examined how to treat urethral injuries in children caused by serious accidents, particularly from car crashes. Three boys with these injuries were treated using one of three surgical methods, all of which were successful. The findings highlight that proper initial care and knowing different surgery techniques can significantly improve outcomes for these young patients. Who this helps: This helps pediatric patients with urethral injuries and their doctors by providing effective treatment options.

Plain English
This study examined three ways to deliver donor cells during in utero hematopoietic cell transplantation (IUHCT) in mice, specifically comparing intravenous (i.v.), intraperitoneal (i.p.), and intrahepatic (i.h.) injections. It found that using the i.v. route allowed for faster and more effective delivery of donor cells to the fetal liver, leading to better short-term and long-term survival rates and more successful engraftment of donor cells. This is important because it shows a way to improve treatment outcomes for babies with certain blood disorders before they are born. Who this helps: This helps patients with congenital hematologic disorders and their families.

Plain English
This study looked at a rare problem called a posterior tibial vein aneurysm in a 36-year-old man who experienced leg pain, shortness of breath, and fainting due to a blood clot in his lungs. After 18 months of discomfort and taking blood thinners, he underwent surgery to remove the aneurysm, which relieved his pain and allowed him to stop taking the medication without complications. This matters because relying on blood thinners alone is not very effective for preventing clots from these types of aneurysms, and surgery can provide a better long-term solution. Who this helps: Patients with tibial vein aneurysms.

Plain English
This study looked at how well surgical teams followed safety protocols by having medical students secretly observe surgeries. They found that 8.2% of surgeries had no marked surgical site, but improvements were made over time, with compliance rising in all safety areas after one year. For example, the surgical checklist was incomplete in 13 cases initially, and by the following year, overall compliance improved after feedback was provided to the surgical teams. Who this helps: This benefits patients undergoing surgery by promoting safer practices in operating rooms.